Company Overview of DNAtriX, Inc.
DNAtriX, Inc., a biotechnology company, engages in the development of an oncoloytic virus platform for the treatment of malignant glioma. The company’s product includes delta24RGD, an oncolytic adenovirus. DNAtriX is based in Houston, Texas.
One Greenway Plaza
Houston, TX 77046
Key Executives for DNAtriX, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.
DNAtriX, Inc. Key Developments
Merck & Company Collaborates with DNAtrix to Study DNX-2401, Keytruda in Glioblastoma
Oct 1 15
Merck & Company has entered into a collaboration with DNAtrix for an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix's oncolytic immunotherapy in combination with Keytruda. The phase 2 study will be on patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.
DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM
Sep 25 15
DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Frank Tufaro, Chief Executive Officer and Director.
FDA Grants Orphan Drug Designation to DNAtrix, Inc.'s DNX-2401 for the Treatment Of Malignant Glioma
Oct 7 14
DNAtrix, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical need. Under the designation, companies are provided with development and commercial incentives for designated compounds. The company's DNX-2401 program has already been granted fast track status. The FDA's orphan drug program designates a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. It can be easier to gain marketing approval for drugs with orphan status, and orphan drugs typically also enjoy extended marketing exclusivity periods. Oncolytic virus therapy is based on the concept of using live viruses to selectively infect and replicate in cancer cells, with minimal destruction of normal tissue. Virus replication amplifies the input dose of the oncolytic virus and helps spread the agent to adjacent tumor cells. Moreover, there is evidence for a long-lasting anti-glioma immune effect that can lead to durable tumor destruction and long-term survival in some patients. DNX-2401, which has been engineered to be highly potent and selective for killing tumors, is currently being evaluated in clinical studies in the United States and Europe.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|